IPHA

Today, July 24th marks International Self Care Day. Here at IPHA, we would like to congratulate the AESGP on 60 years of promoting and advocating for self care.

Over the last two decades 25% of Europe’s share of global medicines R&D investment has been redistributed to other regions of the world. What can Europe do to close the gap? https://lnkd.in/dc6kavDE #WeWontRest

IPHA warmly welcomes the recent announcement by Minister for Health, Stephen Donnelly in relation to the establishment of a new National Clinical Trials Oversight Group. We also welcome the inclusion of Dr Caitriona Walsh on this group who will represent the IPHA voice. Caitriona is Managing Director of Innovative Medicines and Country President at Novartis Ireland and also Chairs IPHA's Clinical Research Exchange Group. We look forward to hearing the practical outcomes from the work of this group which should result in a significant increase in the number of clinical trails available to Irish patients who need them.

Minister Donnelly has announced the establishment of a National Clinical Trials Oversight Group which is tasked with developing recommendations to increase the number of trials taking place in Ireland. The first meeting of the group took place today. https://lnkd.in/eysavpWp

We had a full house at IPHA headquarters today for the second in our series of Summer Leaders Lunches. Today our valued IPHA Affiliates heard insights into the work of our Market Access Advisory Forum (MAAF) and our Clinical Trials Group. Huge thanks to Duggan Caitriona and Killian MacDonald, who chair these groups on behalf of IPHA and facilitated a great session. We are looking forward to seeing everyone again for the last in this series which will take place on August 21st. Elaine Daly Sandra Redmond Keith Hoare Kate Ewings Jim McGrath Eimear O'Leary Robert O'Connor PhD Brian Larkin

Members of the IPHA team were delighted to be in attendance at Leinster House earlier today for the presentation of findings of a new report on the Value of Adult Vaccination in Ireland. During this fascinating panel discussion, we learned about the benefits of proactive rather than reactive healthcare. In other words, preventing illness in the first place rather than treating once it has occurred. Huge thanks to the fascinating panel and to the team at GSK for the invite. Pictured below are Dr Rebecca Cramp, Director of Code & Regulatory Affairs(IPHA), Professor Sam Mc Conkey, Head of Dept of International & Tropical Medicine (RCSI) and Ross Wittham, Communications Lead (GSK).

IPHA is pleased to announce that our Chief Executive, Oliver O’Connor, has recently re-joined the Board of Efpia, the European Federation of Pharmaceutical Industries and Associations. EFPIA’s mission is to create a collaborative environment that enables its members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. At present the Efpia Board are focusing in particular on showing policymakers how the pharmaceutical industry can further contribute to the urgent priority of enhancing European competitiveness and the health of Europeans through developing policies that support innovation and collaborations that encourage the development of medicines and access for all in Europe.  To find out more about the workof Efpia, you can click on this link https://www.efpia.eu/

Fantastic to hear from IPHA leaders Michael O Connell from Biogen UK & Ireland and IPHA President, and Eimear Caslin from GSK and Chair of the Communications Advisory and Advocacy Forum on the great work that IPHA does to promote the pharmaceutical industry nationally and internationally.

I was delighted to attend the IPHA “Meet the Leaders, Summer Lunch & Learn Session” today with my colleague Stephen Horan Horan Grant Thornton Ireland and have the opportunity to hear from two fantastic Irish Pharma Leaders Michael O Connell Country Director Biogen Ireland and President of IPHA and Eimear Caslin General Manager GSK Ireland and Chair of the IPHA Communications Advisory Forum and HR and Finance Committee. It was great to get some valuable insights into the work of IPHA, to hear about the phenomenal work and progress of both GSK and Biogen and discuss some of the key challenges in the industry including access and regulatory changes. Congratulation to Oliver O'Connor, Yvonne (O' Toole) Jones, Dorothy Gray and Eimear O'Leary and everyone in IPHA for hosting such an interesting and enjoyable event.